Sino Biopharmaceutical (DB:SMZ1) - 주가, 뉴스 및 분석

SMZ1 주식 개요

중화인민공화국에서 투자 지주 회사인 Sino Biopharmaceutical Limited는 연구 개발 제약 대기업으로 운영되고 있습니다. 자세한 내용

SMZ1 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	4/6
재무 상태	5/6
배당금	4/6

보상

공정 가치 추정치보다 낮은 72% 에서 거래

수익은 매년 12.91% 증가할 것으로 예상됩니다.

지난 1년간 수익이 70.9% 증가했습니다.

위험 분석

지난 3개월간 상당한 내부자 매도

불안정한 배당 실적

Sino Biopharmaceutical Limited 경쟁사

Dermapharm Holding

XTRA:DMP

€2.0b

Merck KGaA

XTRA:MRK

€61.6b

PharmaSGP Holding

XTRA:PSG

€304.6m

Pierrel

DB:2FJ0

€92.8m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Sino Biopharmaceutical
과거 주가
현재 주가	HK$0.40
52주 최고치	HK$0.48
52주 최저치	HK$0.29
베타	0.69
11개월 변경	-2.68%
3개월 변경 사항	11.98%
1년 변경 사항	-9.09%
33년 변화	-38.32%
5년 변화	-48.28%
IPO 이후 변화	3,950.22%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	SMZ1	DE Pharmaceuticals	DE 마켓
7D	0%	1.4%	0.8%
1Y	-9.1%	-18.4%	9.1%

수익률 대 산업: SMZ1 지난 1년 동안 -18.4 %를 반환한 German Pharmaceuticals 산업을 초과했습니다.

수익률 대 시장: SMZ1 지난 1년 동안 9.1 %를 반환한 German 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is SMZ1's price volatile compared to industry and market?
SMZ1 volatility
SMZ1 Average Weekly Movement	5.9%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

안정적인 주가: SMZ1 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: SMZ1 의 주간 변동성( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2000	24,437	Eric S. Y. Tse	www.sinobiopharm.com

투자 지주 회사인 중화인민공화국 바이오제약 유한회사는 중화인민공화국에서 연구 개발 제약 대기업으로 운영되고 있습니다. 이 회사는 세 가지 부문으로 운영됩니다: 현대화된 중국 의약품 및 화학 의약품, 투자 및 기타. 이 회사는 포커스 브이 브랜드의 안로티닙 염산염 캡슐, 애니케 브랜드의 펜풀리맙 주사, 일리슈 브랜드의 에페말레노그라스틴 알파 주사, 애니유 브랜드의 포말리도마이드 캡슐, 안베이시 브랜드의 베바시주맙 주사, 델리투오 브랜드의 리툭시맙 주사, 사이투오 브랜드의 주사제 트라스투주맙 등 종양학 의약품을 공급하고 있습니다; 톈칭 간메이 브랜드의 이소글리시리진산 마그네슘 주사제와 런중 브랜드의 엔테카비르 분산형 정제 등 간 질환 치료제, 톈칭 수양 브랜드의 흡입용 부데소니드 현탁액과 톈윈 브랜드의 주사제 콜리스티메테이트 나트륨으로 구성된 호흡기 의약품을 판매하고 있습니다.

Sino Biopharmaceutical Limited 기본 사항 요약

Sino Biopharmaceutical 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SMZ1 기본 통계
시가총액	€7.26b
수익(TTM)	€282.70m
수익(TTM)	€3.67b

25.7x

P/E 비율

2.0x

P/S 비율

SMZ1 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SMZ1 손익 계산서(TTM)
수익	CN¥27.79b
수익 비용	CN¥5.23b
총 이익	CN¥22.56b
기타 비용	CN¥20.41b
수익	CN¥2.14b

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	0.12
총 마진	81.16%
순이익 마진	7.71%
부채/자본 비율	22.6%

SMZ1 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

1.8%

현재 배당 수익률

47%

지급 비율

SMZ1 주식 개요

보상

위험 분석

Sino Biopharmaceutical Limited 경쟁사

XTRA:DMP

€2.0b

XTRA:MRK

€61.6b

XTRA:PSG

€304.6m

DB:2FJ0

€92.8m

가격 내역 및 성능

최근 뉴스 및 업데이트

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma

Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Key Executive recently sold €5.9m worth of stock

First half 2024 earnings released: EPS: CN¥0.077 (vs CN¥0.06 in 1H 2023)

Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO

Recent updates

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma

Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Key Executive recently sold €5.9m worth of stock

First half 2024 earnings released: EPS: CN¥0.077 (vs CN¥0.06 in 1H 2023)

Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO

Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma

First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023)

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma

Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024

Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet

Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)"

Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma

Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in FY 2022)

Executive Chairwoman of the Board recently bought €695k worth of stock

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.14 in FY 2022)

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Now 22% undervalued

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Upcoming dividend of HK$0.02 per share at 2.7% yield

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA

First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022)

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023

New minor risk - Share price stability

Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023

Key Executive recently bought €4.0m worth of stock

Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms

Upcoming dividend of HK$0.06 per share at 3.0% yield

Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine

Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection)

Executive Vice Chairwoman of the Board recently bought €2.4m worth of stock

Full year 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.78 in FY 2021)

Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation

Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203"

Less than half of directors are independent